Analyst firms · Argus Research · IART
Argus Research IART price target and rating history
Integra LifeSciences Holdings Corporation (IART) · Health Care
Argus Research rates Integra LifeSciences Holdings Corporation (IART) Buy with a $25 price target, as of its latest action on Jun 18, 2026. It has published 4 rating actions on IART since June 2023, including 2 upgrades and 2 downgrades. Across 4 firms with a IART price target in the last 12 months, the median target is $19. Argus Research's $25 is 32% above that.
- Current rating
- Buy
- Price target
- $25
- Median target, all firms
- $19
- Actions on IART
- 4
Every Argus Research rating on IART
- Jun 18, 2026
- Apr 15, 2026
- Mar 31, 2025
- Jun 8, 2023
How other firms rate IART
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $19 | Jul 28, 2026 |
| BMO Capital Markets | Market Perform | $19 | Jul 9, 2026 |
| Argus Research | Buy | $25 | Jun 18, 2026 |
| Citigroup | Neutral | $16 | May 28, 2026 |
Questions about Argus Research and IART
- What is Argus Research's price target for IART?
- Argus Research's latest stated price target for Integra LifeSciences Holdings Corporation (IART) is $25, from its action on Jun 18, 2026.
- What is Argus Research's rating on IART?
- Argus Research rates IART Buy, a bullish rating, as of Jun 18, 2026.
- When did Argus Research last change its view on IART?
- On Jun 18, 2026, Argus Research upgrades to Buy from Hold, price target $25.
- How does Argus Research's IART target compare with other analysts?
- Across 4 firms with a IART price target in the last 12 months, the median target is $19. Argus Research's $25 is 32% above that.
More IART rating histories
All Argus Research ratingsIART news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.